|
BioMimetic Therapeutics, Inc. |
|
|
389-A Nichol Mill Lane
Franklin, TN 37067 USA
phone:615-844-1280
fax:615-844-1281
|
|
| Symbol |
BMTI |
| Exchange |
NASDAQ |
| Founded |
2001 |
| Employees |
85 |
|
|
| www.biomimetics.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drug-Device Combination Products to treat Musculoskeletal Injury |
|
| Management |
| Sam Lynch, D.M.D., D.M.Sc., President, Chief Executive Officer; William Beasley, VP; Larry Bullock, Chief Financial Officer; Earl Douglas, General Counsel; Steve Hirsch, COO & Executive Vice President; John McKay, Vice President; James Monsor, Vice President; Russ Pagano, Ph.D., vice president of regulatory and clinical affairs; Leo Snel, Senior Vice President |
| |
|
|
|
|
|
|
|
| Keywords |
| Orthopedics, spine, ortho joint, reconstruction, ortho joint, reconstruction, advamed, bone fractures |
|
|
|
| Description |
|
BioMimetic Therapeutics, Inc. develops bio-active drug-device combination products to speed the healing of musculoskeletal injuries and diseases in periodontal, orthopedic, craniofacial, spine and sports injury indications. The company's products combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration. |
|
| Products / Services |
BioMimetic's GEM 21S is an FDA-approved product used to treat bone loss experienced in periodontal disease. The Augment Bone Graft (formerly GEM OS1 Bone Graft) is designed to stimulate bone regeneration; its targeted uses are in open fracture reduction and for fractures requiring surgery (foot and ankle fusion). Augment Bone Graft (formerly GEM OS2 Bone Graft) is an injectable product for the treatment of non-surgical fracture injuries. Cartilage, ligament and tendon product candidates (Augment C and Augment LT) using proprietary technology are also being developed to stimulate cartilage, ligament, and tendon repair and regeneration.
|
|
| Technology / Differentiation |
| BioMimetic's Augment family of products utilize the FDA-approved recombinant human platelet derived growth factor (rhPDGF-BB) in combination with scaffolding materials that have a history of demonstrated safety and efficacy. rhPDGF-BB attracts cells necessary for tissue healing through chemotaxis, while also stimulating an increase in the number of healing cells through mitogenesis; these processes expand the number of cells available for the repair process. In addition, published in vivo and in vitro studies demonstrate that rhPDGF-BB may enhance processes important in new blood vessel formation at the wound site, a process critical for wound healing. Consequently, rhPDGF-BB has been shown to enhance bone fracture repair and to strengthen the skeleton throughout the body. |
|
| Market / Customers |
According to Espicom, the global orthobiologics market was estimated to be worth $4.2 billion in 2007 with an annual growth rate of 17%. Though still in its early stage, orthobiologics is the fastest growing orthopedic segment and presents vast opportunities for investment.
|
|
| Status |
| As of December 31, 2008, 436 patients were enrolled in Biomimetic's North American pivotal clinical study assessing the safety and efficacy of Augment Bone Graft; the company closed enrollment for this study at that time. Deloitte ranked Biomimetic Therapeutics number 181 on its 2008 Technology Fast 500, which ranks the 500 fastest growing technology, media, telecommunications and life sciences companies in North America. Since BioMimetic's dental business, including GEM 21S, is now owned by Luitpold Pharmaceuticals, the company is primarily focused on its orthopedic products and product candidates. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
